Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy

American Journal of Kidney Diseases

Volumn 36, Issue 6, 2000, Pages 1193-1200

  Kramer, Ludwig ^a   Gendo, Alexandra ^a   Madl, Christian ^a   Ferrara, Ilse ^a   Funk, Georg ^a   Schenk, Peter ^a   Sunder Plassmann, Gere ^a   Hörl, Walter H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Artificial liver support; Biocompatibility; BioLogic DT; Charcoal suspension; Cytokines; Disseminated intravascular coagulation (DIC); Elastase; Liver dialysis; Platelets

Indexed keywords

CHARCOAL; CUPROPHANE; ELASTASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERLEUKIN 6; SORBENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ARTIFICIAL LIVER; BIOCOMPATIBILITY; BLEEDING; BLOOD PRESSURE; BODY TEMPERATURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIALYSIS; DIALYSIS MEMBRANE; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HEART RATE; HEMOPERFUSION; HEPATIC ENCEPHALOPATHY; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL STANDARD UNIT; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0033647082     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.19834     Document Type: Article

References (40)

1. Current concepts in the pathophysiology of hepatic encephalopathy
2. Hepatic encephalopathy: Treatment
3. Ammonia: A key factor in the pathogenesis of hepatic encephalopathy
4. The relationship between plasma and brain quinolinic acid levels and the severity of hepatic encephalopathy
5. Natural benzodiazepines and hepatic encephalopathy
6. Use of bioartificial and artificial liver support devices
7. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure
8. Biocompatibility of coated and uncoated charcoal during haemoperfusion in healthy dogs
9. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT)
10. Neurologic improvement of patients with hepatic failure and coma during sorbent suspension dialysis
11. Evaluation of the BioLogic-DT sorbent-suspension dialyzer in patients with fulminant hepatic failure
12. Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the Biologic-DT
13. Bacterial and fungal infection in acute liver failure
14. Evaluation of extracorporeal bioartificial liver devices
15. Influence of the dialysis membrane on outcome of ESRD patients
16. Plasma levels of granulocyte elastase during hemodialysis: Effects of different dialyzer membranes
17. Platelet-leukocyte aggregates during hemodialysis: Effect of membrane type
18. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis
19. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: Dissociation of complement activation and neutropenia from neutrophil degranulation
20. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factoralpha levels during hemodialysis
21. Prospective crossover trial of the influence of vliamin E-coated dialyzer membranes on T-cell activation and cytokine induction
22. Effect of the dialysis membrane in the treatment of patients with acute renal failure
23. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis
24. Biocompatible membranes in acute renal failure: Prospective case-controlled study
25. Haemodialysismembrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: A prospective randomised multicentre trial
26. Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease
27. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis
28. Disseminated intravascular coagulation
29. Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic-DT
30. Disseminated intravascular coagulation in liver cirrhosis
31. Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis
32. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis
33. The inactivation of antithrombin III by serum elastase in patients with surgical infections
34. Correlation between increased granulocyte elastase release and activation of blood coagulation in patients with lung cancer
35. Disseminated intravascular coagulation in liver cirrhosis: Fact or fiction?
36. Heparin blunts endotoxin-induced coagulation activation
37. Lepirudin blunts endotoxin-induced coagulation activation
38. Impairment of citrate metabolism in acute hepatic failure
39. A controlled study of the BioLogic-DT system in chronic hepatic encephalopathy
40. Different complement and granulocyte activation in patients dialyzed with PMMA dialysers